December 21 2017

Resignation of Chief Medical Officer

Irina Antonijevic, MD PhD resigns from her position as CMO

Wuerzburg, Germany – December 21, 2017 – vasopharm GmbH, a privately held biopharmaceutical company focusing on novel therapeutics for the treatment of cerebrovascular diseases, regrets to announce that Dr Irina Antonijevic (CMO) will return to Boston as a result of a family health issue.  She has informed the company that she will no longer be able to fulfil her role in Europe and her formal resignation will be effective from 31st December 2017. 

Dr Antonijevic commented:
"I am deeply disappointed to be leaving vasopharm at this time and this decision in no way reflects on the prospects for the current phase III NOSTRA trial or VAS 203 in the treatment of Traumatic Brain Injury (and its potential in other indications).  I have great confidence in the NOSTRA III trial and the vasopharm team but my family will always remain my priority."

Christian Wandersee (CEO) states:
"We are saddened to be losing Irina, a valuable and popular member of our team.  However, we respect and understand her decision and wish her and her family the very best for the future.  Her responsibilities in the phase III study will be taken over by Dr Frank Tegtmeier and Dr Reinhard Schinzel who performed this role in the phase II study."